U.S. flag An official website of the United States government
  1. Home
  2. Emergency Preparedness and Response
  3. Counterterrorism and Emerging Threats
  4. Medical Countermeasures Initiative (MCMi)
  5. About MCMi
  6. MCMi News and Events
  1. About MCMi

MCMi News and Events

Medical countermeasure and public health emergency news and events from FDA and partners

News & events on typewriter

Featured news and events

FDA funding opportunity - In February 2018, FDA revised its Broad Agency Announcement (BAA) for research and development to support regulatory science and innovation. MCM-related research submissions are encouraged under area 7: Facilitate Development of Medical Countermeasures to Protect Against Threats to U.S. and Global Health Security. The current BAA announcement will remain open until further notice, but proposers are encouraged to submit white papers by March 29, 2019 for fiscal year 2019 awards. More about MCM-related extramural research
  • September 6, 2019: From HHS - HHS has issued RFPs in support of BARDA clinical trials, including contract research organizations to plan and conduct clinical trials (respond by October 21, 2019); establish a new statistical and data coordinating center (respond by October 7, 2019); and support the establishment of a new biospecimen storage facility (respond by October 7, 2019).
  • February 22, 2019: NIAID has posted a BAA for research areas including: Development of Radiation/Nuclear Medical Countermeasures, Development of Therapeutic Products for Antibiotic Resistant Bacteria, and Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria.

  • December 3, 2018: From NIH - Antimicrobial Resistance Diagnostic Challenge names five finalists - Selected entrants will receive $100,000 to further develop and test prototypes to improve detection of drug-resistant bacteria or differentiate between a bacterial and viral infection. Antibiotic resistant bacteria are a rising public health threat and cause at least 2 million infections and 23,000 deaths each year in the United States, according to CDC. Drug resistance can also erode the effectiveness of drugs provided as part of a medical response to bioterrorism, such as an anthrax attack. NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and ASPR’s Biomedical Advanced Research and Development Authority (BARDA) are each contributing $10 million to the Challenge. The Challenge also was developed with technical and regulatory expertise from the CDC, FDA, and NIH Office of the Director.

  • May 1, 2018: Slides are now available from FDA Sentinel Industry Day 2018 - also see FDA's Sentinel Initiative

  • November 6, 2017: The HHS Office of Biomedical Advanced Research and Development Authority (BARDA) has issued a Broad Agency Announcement (BAA) seeking proposals for the advanced research and development of medical countermeasures (MCMs) for chemical, biological, radiological and nuclear (CBRN) agents, pandemic influenza, and emerging infectious diseases that threaten the U.S. civilian population. Respond by October 31, 2019.

Connect with us

Follow Us On Twitter Follow @FDA_MCMi on Twitter

MCMi email updates View previous editions of the MCMi email newsletter

For more information


Emergency use

Guidance and industry information

Public health emergency response updates and MCM-related issues

Product shortages and availability

More FDA news and events

  • FDA Newsroom - press announcements, fast facts, speeches, and more
  • FDA Voices - perspectives from FDA experts



Sign up to receive email alerts on emergency preparedness and response topics from FDA, including medical countermeasures and emerging infectious diseases.